Real-world drug survival and treatment outcome of ixekizumab in patients with spondyloarthropathies.
Al-Awuad L · 2026 · Frontiers in immunology
Reading the original? How to read a paper.
What this paper found
In a real-world cohort on ixekizumab (Taltz), about 60 percent of people with ankylosing spondylitis were still on the drug at one year and the median time on treatment was just under two years, with lack of effect the main reason for stopping and side effects uncommon. Starting it earlier in the treatment sequence, rather than third-line or later, more than halved the chance of stopping.
Why this is on the map
Real-world persistence data for an IL-17 drug outside trials, with the order-of-use effect that registries keep finding.
On the map under these threads
DOI: 10.3389/fimmu.2026.1924119 · opens in a new tab. The full paper is on the publisher’s site, not here.
Related papers on the board
Papers sharing one or more threads with this one.
A disease-associated gene desert directs macrophage inflammation through ETS2
Nature
Identified a single 'switch' gene called ETS2, sitting on chromosome 21, that turns immune cells inflammatory across AS, IBD, and several other related diseases. Because no current drug targets ETS2, this points to a treatment direction beyond what's already available with TNF and IL-17 blockers.
Gut microbiota and ankylosing spondylitis: current insights and future challenges
Microbial Cell
Comprehensive review of how gut bacterial imbalance disrupts the IL-23/IL-17 inflammatory pathway and weakens the intestinal barrier in AS. Identifies the lack of standardised methodology and large cohorts as the bottleneck for translating this into treatments.
Dysbiosis of Gut Microbiota in Ankylosing Spondylitis Patients
Dove Medical Press
Confirms that intestinal dysfunction precedes or amplifies systemic inflammation in AS. Frames gut microbiota as the convergence point where genetic, immune, and microbial factors meet.
Current status and emerging trends in biological therapies for ankylosing spondylitis: a bibliometric analysis (2004–2024)
Medicine (LWW)
Bibliometric analysis of biological therapies for AS over 2004-2024. Confirms three pillars, TNF, IL-17, and JAK inhibitors, and a persistent inadequate response in a meaningful subset of patients across all three classes.